CUE
CUE
NASDAQ · Biotechnology

Cue Biopharma Inc

$30.43
+5.04 (+19.85%)
As of Jun 29, 10:32 PM ET ·
Financial Highlights (FY 2026)
Revenue
35.62M
Net Income
-34,497,100
Gross Margin
Profit Margin
-96.9%
Rev Growth
+180.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 40.2% 40.2%
Operating Margin -96.7% -402.2% -10.0% -9.6%
Profit Margin -96.9% -416.1% -8.8% -9.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 35.62M 17.68M 17.52M 19.24M
Gross Profit 7.05M 7.74M
Operating Income -34,431,288 -71,104,630 -1,757,465 -1,843,438
Net Income -34,497,100 -69,679,191 -1,532,650 -1,824,826
Gross Margin 40.2% 40.2%
Operating Margin -96.7% -402.2% -10.0% -9.6%
Profit Margin -96.9% -416.1% -8.8% -9.5%
Rev Growth +180.1% -14.7% +0.6% +3.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 2.58M 12.69M 12.70M
Total Equity 10.40M 8.33M 9.35M
D/E Ratio 0.25 1.52 1.36
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -33,996,347 -74,344,734 -1,913,244 -2,419,019
Free Cash Flow -1,533,941 -1,392,757